Inflammatory molecule release by β-amyloid-treated T98G astrocytoma cells: Role of prostaglandins and modulation by paracetamol

European Journal of Pharmacology

Volumn 360, Issue 1, 1998, Pages 55-64

  Landolfi, Carla ^a   Soldo, Lucia ^a   Polenzani, Lorenzo ^a   Apicella, Claudia ^a   De Joannon, Alessandra Capezzone ^a   Coletta, Isabella ^a   Di Cesare, Franco ^a   Brufani, Mario ^b   Pinza, Mario ^a   Milanese, Claudio ^a  

^a Università Politecnica delle Marche ACRAF Gruppo Angelini   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Alzheimer's disease; Interleukin 6; Non steroidal anti inflammatory drug; Prostaglandin

Indexed keywords

AMYLOID BETA PROTEIN; INDOMETACIN; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROSTAGLANDIN;

ARTICLE; ASTROCYTOMA CELL; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS;

ACETAMINOPHEN; AMYLOID BETA-PROTEIN; ANALGESICS, NON-NARCOTIC; ASTROCYTOMA; CULTURE MEDIA, CONDITIONED; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DINOPROSTONE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1; INTERLEUKIN-6; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0032582545     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00663-3     Document Type: Article

References (48)

1. Aisen P.S., Davis K.L. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am. J. Psychiatry. 151:1994;1105-1113.
2. Andersen K., Launer L.J., Ott A., Hoes A.W., Breteler M.M.B., Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? Neurology. 45:1995;1441-1445.
3. Barnum S.R., Jones J.L., Benveniste E.N. Interleukin-1 and tumor necrosis factor-mediated regulation of C3 gene expression in human astroglioma cells. Glia. 7:1993;225-236.
4. Bethea J.R., Chung I.Y., Sparacio S.M., Gillespie G.Y., Benveniste E.N. Interleukin-1β induction of tumor necrosis factor-α gene expression in human astroglioma cells. J. Neuroimmunol. 36:1992;179-191.
5. Bezzi P., Carmignoto G., Pasti L., Vesce S., Rossi D., Lodi Rizzini B., Pozzan T., Volterra A. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature. 391:1998;281-285.
6. Bignami A., Eng L.F., Dahl D., Uyeda C.T. Localization of the glial fibrillary acidic protein in astrocytes by immunofluorescence. Brain Res. 43:1972;429-435.
7. Breitner J.C.S. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu. Rev. Med. 47:1996;401-411.
8. Breitner J.C.S., Gau B.A., Welsh K.A., Plassman B.L., McDonald W.M., Helms M.J., Anthony J.C. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology. 44:1994;227-232.
9. Cadman E.D., Witte D.G., Lee C.M. Regulation of the release of interleukin-6 from human astrocytoma cells. J. Neurochem. 63:1994;980-987.
10. Cinque S., Willems J., Depraetere S., Vermeire L., Joniau M. 'In vitro' effect of interleukin-1β on human glioma cell lines: regulation of cell proliferation and IL-6 production. Immunol. Lett. 34:1992;267-271.
11. Clissold S.P. Paracetamol and phenacetin. Drugs. 32(Suppl. 4):1986;46-59.
12. Colton C.A., Gilbert D.L. Production of superoxide anions by a CNS macrophage, the microglia. FEBS Lett. 223:1987;284-288.
13. Cotman C.W., Pike C.J., Copani A. β-amyloid neurotoxicity: a discussion of in vitro findings. Neurobiol. Aging. 13:1992;587-590.
14. Davies, P., 1994. Neuronal abnormalities, not amyloid, are the cause of dementia in Alzheimer's disease. In: Terry, R.D., Katzman, R., Bick, K.L. (Eds.), Alzheimer's Disease. Raven Press, New York, NY, pp. 327-333.
15. Eddleston M., Mucke L. Molecular profile of reactive astrocytes: implications for their role in neurological disease. Neuroscience. 54:1993;15-36.
16. Eikelenboom P., Zhan S.S., van Gool W.A., Allsop D. Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol. Sci. 15:1994;447-450.
17. 2 levels in mouse brain. Eur. J. Pharmacol. 179:1990;25-34.
18. Flower R.J., Vane J.R. Inhibition of prostaglandine synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature. 240:1972;410-411.
19. Gitter B.D., Cox C.M., Rydel R.E., May P.C. Amyloid β peptide potentiates cytokine secretion by interleukin-1β-activated human astrocytoma cells. Proc. Natl. Acad. Sci. USA. 92:1995;10738-10741.
20. Griffin W.S.T., Stanley L.C., Ling C., White L., MacLeod V., Perrot L.J., White C.L., Araoz C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. USA. 86:1989;7611-7615.
21. Guilian D., Hoverkamp L.J., Li J., Karshin W.L., Yu J., Tom D., Li X., Kirkpatrick J.B. Senile plaques stimulate microglia to release a neurotoxin found in Alzheimer brain. Neurochem. Int. 27:1995;119-137.
22. Hardy J., Allsop D. Amyloid deposition as central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12:1991;383-388.
23. Hertz F., Cloarec A. Pharmacology of free radicals: recent views on their relation to inflammatory mechanisms. Life Sci. 34:1984;713-720.
24. Kasahara T., Mukaida N., Yamashita K., Yagisawa H., Akaoshi T., Matsushima K. IL-1 and TNFα induction of IL-8 and monocyte chemotactic and activating factor (MCAF) mRNA expression in a human astrocytoma cell line. Immunology. 74:1991;60-67.
25. Lorenzo A., Yankner B.A. β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo Red. Proc. Natl. Acad. Sci. USA. 91:1994;12243-12247.
26. Marshall P.J., Kulmacz R.J., Lands W.E.M. Constraints on prostaglandin biosynthesis in tissues. J. Biol. Chem. 262:1987;3510-3517.
27. Masliah E., Mallory M., Deerinck T., DeTeresa R., Lamont S., Miller A., Terry R.D., Carragher B., Ellisman M. Re-evaluation of the structural organization of neuritic plaques in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 52:1993;619-632.
28. Masters C.L., Simms G., Weinman N.A., Multhoup G., McDonnaald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA. 82:1985;4245-4249.
29. McGeer P.L., McGeer E.G. The inflammatory response system of the brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Rev. 21:1995;195-218.
30. McGeer P.L., McGeer E.G., Rogers J., Sibley J. Anti-inflammatory drugs and Alzheimer's disease. Lancet. 335:1990;1037.
31. Moynagh P.N., Williams D.C., O'Neill L.A. Activation of NF-kB and induction of vascular cell adhesion molecule-1 and intracellular adhesion molecule-1 in human glial cells by IL-1. J. Immunol. 153:1994;2681-2690.
32. Pike C.J., Walencewicz A.J., Glabe C.G., Cotman C.W. Aggregation-related toxicity of synthetic β-amyloid protein in hippocampal cultures. Eur. J. Pharmacol. 207:1991;367-368.
33. Pollack S.J., Sadler I.I.J., Hawtin S.R., Tailor V.J., Shearman M.S. Sulfonated dyes attenuate the toxic effects of β-amyloid in a structure-specific fashion. Neurosci. Lett. 197:1995;211-214.
34. Prescott L.F. Kinetics and metabolism of paracetamol and phenacetin. Br. J. Clin. Pharmacol. 10(Suppl. 2):1980;291S-298S.
35. Price D. New perspectives on Alzheimer's disease. Annu. Rev. Neurosci. 9:1986;489-512.
36. Rogers J. Inflammation as a pathogenic mechanism in Alzheimer's disease. Arzneim. Forsch./Drug Res. 45:1995;439-442.
37. Rogers J., Kirby L.C., Hempelman S.R., Berry D.L., McGeer P.L., Kaszniak A.W., Zalinski J., Cofield M., Mansukhani L., Willson P., Kogan F. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 43:1993;1609-1611.
38. Rosenmaln S.J., Shrikant P., Dubb L., Benveniste E.N., Ransohoff R.M. Cytokine-induced expression of vascular cell adhesion molecule-1 (VCAM-1) by astrocytes and astrocytoma cell lines. J. Immunol. 154:1995;1888-1899.
39. Selkoe D.J. Cell biology of the amyloid β-protein precursor and the mechanism of Alzheimer's disease. Annu. Rev. Cell. Biol. 10:1994;373-403.
40. Shearman M.S., Ragan C.I., Iversen L.L. Inhibition of PC12 cell redox activity is a specific early indicator of the mechanism of β-amyloid-mediated cell death. Proc. Natl. Acad. Sci. USA. 91:1994;1470-1474.
41. Stewart W.F., Kawas C., Corrada M., Metter E.J. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 48:1997;626-632.
42. Tordjman C., Coge F., Andre N., Rique H., Spedding M., Bonnet J. Characterisation of cyclooxygenase 1 and 2 expression in mouse resident peritoneal macrophages in vitro; interactions of non steroidal anti-inflammatory drugs with COX2. Biochim. Biophys. Acta. 1256:1995;249-256.
43. Tallarida, R.J., Murray, R.B., 1987. Manual of pharmacological calculations with computer programs. Springer, New York, NY.
44. Walker D.G., McGeer P.L. Complement gene expression in neuroblastoma and astroglioma cell lines of human origin. Neurosci. Lett. 157:1993;99-102.
45. 2 or glucocorticoids. Scand. J. Immunol. 32:1990;601-609.
46. Wood P.L. Microglia: a possible cellular target for pharmacological approaches to neurodegenerative disorders. Dev. Neurol. Pharmacol. 7:1994;138-157.
47. Yamagata K., Andreasson K.I., Kaufmann W.E., Barnes C.A., Worley P.F. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron. 11:1993;371-386.
48. Yankner B.A., Duffy L.K., Kirschner D.A. Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science. 250:1990;279-282.